GlassScriptPhysician profile
Carrie E Weaver
NPI 1851065825
$995.98
in general payments reported to CMS, 2019-2025
13 companies · $785 in 2025
The $785 reported for 2025 was more than what 76% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $111 · 2024: $99.54 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $995.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $284.33 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Vanda Pharmaceuticals INC. | $114.38 | 2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $77.55 | 2025 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $70.69 | 2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $68.74 | 2025 | Trintellix |
| Axsome Therapeutics, INC. | $67.19 | 2025 | Auvelity |
| Collegium Pharmaceutical, INC. | $63.64 | 2025 | Jornay Pm |
| Lundbeck LLC | $62.49 | 2025 | Rexulti |
| Noven Therapeutics, LLC | $60.63 | 2025 | Xelstrym, Secuado |
| Abbvie INC. | $38.51 | 2025 | |
| Janssen Pharmaceuticals, INC | $37.83 | 2025 | Invega Sustenna, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.06 | 2025 | Caplyta |
| Neos Therapeutics, LP | $21.94 | 2025 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrie Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.